BCBogdan Czerniak

Bogdan Czerniak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bogdan Czerniak has a total of 407 co-authors. Here are the top co-authors by number of shared publications:

  • Jolanta Bondaruk

    Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA

    24 shared publications
  • Sangkyou Lee

    Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA

    23 shared publications
  • Colin Dinney

    Department of Urology The University of Texas MD Anderson Cancer Center Houston TX USA

    19 shared publications
  • Tadeusz Majewski

    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

    19 shared publications
  • Charles C. Guo

    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA

    15 shared publications
  • David McConkey

    Johns Hopkins Greenberg Bladder Cancer Institute Johns Hopkins University Baltimore MD USA

    15 shared publications

Latest Publications

  • Open Access

    Supplementary Methods S1 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture

    by Kai Yu, Jianfeng Chen, Yu-Yi Chu, Sajith Nair, Emanuele Crupi, Elshad Hasanov, Ying Mei, Xueshuai Han, Yang Liu, Yunhe Liu, et al.

    Supplementary Methods file contains extended methods, including the processing and analysis of multiple sequencing datasets.

  • Open Access

    Supplementary Tables S1-S6 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture

    by Kai Yu, Jianfeng Chen, Yu-Yi Chu, Sajith Nair, Emanuele Crupi, Elshad Hasanov, Ying Mei, Xueshuai Han, Yang Liu, Yunhe Liu, et al.

    Supplementary Tables file contains key information and supporting datasets. Table S1 | Clinicopathological features of the 22 MIBC patients. Table S2 | The top 50 most significantly differentially expressed genes between the 15 single cell clusters. Table S3 | GSEA pathway enrichment results for 4 spatial clusters. Table S4 | Clinical characteristics and spatial tumor state composition across samples. Table S5 | Bootstrap-based robustness analysis of spatial tumor state proportions. Table S6 | The top 50 most significantly differentially expressed genes between the 4 spatial clusters.

  • Open Access

    Supplementary Figures S1-S15 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture

    by Kai Yu, Jianfeng Chen, Yu-Yi Chu, Sajith Nair, Emanuele Crupi, Elshad Hasanov, Ying Mei, Xueshuai Han, Yang Liu, Yunhe Liu, et al.

    Supplementary Figures file contains Supplementary Figures S1–S15. Figure S1 | Pathology-guided spatial annotation across 22 MIBC tumors. Figure S2 | Validation of spatial deconvolution accuracy and cell-type compartmentalization. Figure S3 | Additional tumors demonstrating spatial CNV-based subclones and transcriptional divergence. Figure S4 | Cross-platform concordance of CNV profiles inferred from spatial transcriptomics and WES. Figure S5 | Transcriptional and functional features across the luminal-to-basal differentiation continuum. Figure S6 | Single-cell analysis recapitulates the spatial luminal-to-basal differentiation continuum. Figure S7 | Spatial validation of lineage-associated EGFR and FGFR3 expression patterns. Figure S8 | Lineage-associated expression of FGFR3–EGFR signaling and transcriptional regulators across normal tissue, tumor states, and independent cohorts. Figure S9 | Pathology-guided spatial annotation across all MIBC tumors. Figure S10 | Spatial tumor states associate with chemotherapy response and stress-related gene expression. Figure S11 | NECTIN4 expression is enriched in luminal tumors and declines at the tumor-normal boundary. Figure S12 | Subtype-associated genomic alterations and their relationship with basal program activity. Figure S13 | Associations between basal signature scores and clinical or molecular features across MIBC cohorts. Figure S14 | Pathologist-guided TLS annotation confirms spatial transcriptomic predictions. Figure S15 | Lineage-associated chemokine programs and tumor–TLS interactions.

  • Open Access

    De Novo and Postradiation Adenocarcinoma of the Urethra

    by Miao Zhang, Raghu Vikram, Junhyoun Sung, Peng Wei, Kanishka Sircar, Patricia Troncoso, Curtis Pettaway, Pheroze Tamboli, Bogdan Czerniak

    Herein, we report the results of clinicopathologic and radiographic analyses of 55 patients with primary adenocarcinoma of the urethra. Their ages at diagnosis ranged from 42 to 88 years (mean: 66 y). Twenty-six patients were male and 29 were female (ratio: 1.0:1.1). We noted 2 distinct groups of cases: de novo urethral adenocarcinoma (n=45) and urethral adenocarcinoma in patients after radiation therapy for prostatic adenocarcinoma (n=10), defined as postradiation adenocarcinoma. Postradiation tumors developed 8 to 25 years (mean: 15.6 y) after radiation therapy. Eight patients underwent brachytherapy. Among the 45 patients with de novo adenocarcinoma, 29 were female, for a female-to-male ratio of 1.8 to 1.0. In 17 female patients with de novo urethral adenocarcinoma, tumors developed in a urethral diverticulum. Histologically, urethral adenocarcinomas exhibited adenocarcinoma not otherwise specified or clear cell, mucinous, enteric, and adenoid cystic carcinoma morphology. In 2 cases of de novo adenocarcinoma and 3 cases of postradiation adenocarcinoma, the tumors progressed to sarcomatoid carcinoma. The mean disease-specific survival time for the entire cohort was 100.35 months. As reflected by the Kaplan-Meier curves for these patients, the patterns of disease-specific survival were similar in the de novo and postradiation groups.

  • Open Access

    A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture

    by Kai Yu, Jianfeng Chen, Yu-Yi Chu, Sajith Nair, Emanuele Crupi, Elshad Hasanov, Ying Mei, Xueshuai Han, Yang Liu, Yunhe Liu, et al.

    Muscle-invasive bladder cancer (MIBC) is clinically heterogeneous, and current molecular subtyping does not capture the spatial organization of tumor states and microenvironmental context. Here, we construct a spatial atlas of MIBC by integrating spatial transcriptomics from 22 tumors with matched bulk RNA and whole-exome sequencing data. We identify a continuous, spatially organized luminal-to-basal axis within individual tumors that is associated with greater chromosomal instability and transcriptional plasticity. Luminal tumor cores are enriched for FGFR3 and NECTIN4, whereas basal-like states localize toward invasive margins and are associated with elevated EGFR signaling, epithelial–mesenchymal transition, genomic instability, immune infiltration, and greater chemotherapy sensitivity. Spatial analyses further reveal lineage- and location-associated differences in tertiary lymphoid structure states. Pan-cohort analyses across over 3,000 tumors confirm conserved FGFR3–EGFR lineage exclusivity and associated immune programs. Together, these findings define a spatial framework for understanding lineage states, immune architecture, and therapeutic vulnerabilities in MIBC.


  • Open Access

    Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer

    by Sangkyou Lee, Sung Yun Jung, Pawel Kuś, Jolanta Bondaruk, June Goo Lee, Roman Jaksik, Nagireddy Putluri, Khanh N Dinh, David Cogdell, Huiqin Chen, et al.

    Multiplatform mutational and gene expression profiling complemented with proteomic and metabolomic spatial mapping were used on the whole‐organ scale to identify the molecular profile of bladder cancer evolution from field effects. Analysis of the mutational landscape identified three types of mutations, referred to as α, β, and γ. Time modeling of the mutations revealed that carcinogenesis may span 30 years and can be divided into dormant and progressive phases. The α mutations developed in the dormant phase. The progressive phase lasted 5 years and was signified by expanding β mutations, but it was driven to invasive cancer by γ mutations. The mutational landscape emerged on a background of disorganized urothelial differentiation, activated epithelial‐mesenchymal transition, and enhanced immune infiltration with T‐cell exhaustion. Complex dysregulation of mitochondrial energy metabolism with downregulation of oxidative phosphorylation emerged as the leading mechanism driving the progression of mucosal field effects to invasive cancer. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • Open Access

    Urethral Adenocarcinoma: A Rare Malignancy With Poor Oncologic Outcomes Despite Neoadjuvant Treatment and Consolidative Therapy

    by Landan P. MacDonald, Jamaal C. Jackson, Tarek I. Lawen, Ramez Kouzy, Lauren Colbert, Miao Zhang, Bogdan A. Czerniak, Curtis A. Pettaway, Kelly K. Bree

    Purpose: Primary urethral adenocarcinoma (PAC) is a rare malignancy associated with poor outcomes. There are 2 primary subtypes—clear cell adenocarcinoma (CCAC) and non–clear cell adenocarcinoma (nCCAC). In this study, we compare oncologic outcomes between CCAC vs nCCAC histological subtypes and describe differences in treatment modalities. Materials and Methods: We performed a retrospective review of patients diagnosed with PAC at our institution between 1993 to 2024. Survival analysis was stratified by histologic subtype (CCAC vs nCCAC) and primary treatment modality. Survival outcomes were stratified by patient age, neoadjuvant therapy (NAT), primary treatment modality, clinical stage, and histological subtype. Results: Of the 35 patients identified, the majority were female, were Black, and presented with locally advanced disease. Most of the patients were treated with radiotherapy (XRT) or surgical extirpation. There were no significant differences in clinical staging or histologic subtype between the 2 treatment modalities. Ten patients were treated with XRT, and 21 patients underwent primary surgical extirpation. Most of the patients received NAT. Locally advanced disease on final pathology was common for both histological subtypes. No patients were downstaged after surgical extirpation, despite nearly all receiving NAT. Survival was significantly better for CCAC vs nCCAC. There was no statistical difference in survival when comparing by treatment modality. Conclusions: PAC represents a rare, aggressive form of cancer. Favorable outcomes among the CCAC cohort may reflect a more favorable disease biology. Despite most of the patients receiving NAT, there were no patients with pathologic downstaging suggesting current neoadjuvant regimens are suboptimal and novel systemic strategies are needed for tumor downstaging to facilitate optimal local tumor control and improved oncologic outcomes.


  • Open Access

    METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics

    by Jiahui Jiang, Yunhe Liu, Jiangjiang Qin, Jianfeng Chen, Jingjing Wu, Melissa P. Pizzi, Rossana Lazcano, Kohei Yamashita, Zhiyuan Xu, Guangsheng Pei, et al.

    Recent advances in spatial transcriptomics (ST) techniques provide valuable insights into cellular interactions within the tumor microenvironment (TME). However, most analytical tools lack consideration of histological features and rely on matched single-cell RNA sequencing data, limiting their effectiveness in TME studies. To address this, we introduce the Morphology-Enhanced Spatial Transcriptome Analysis Integrator (METI), an end-to-end framework that maps cancer cells and TME components, stratifies cell types and states, and analyzes cell co-localization. By integrating spatial transcriptomics, cell morphology, and curated gene signatures, METI enhances our understanding of the molecular landscape and cellular interactions within the tissue. We evaluate the performance of METI on ST data generated from various tumor tissues, including gastric, lung, and bladder cancers, as well as premalignant tissues. We also conduct a quantitative comparison of METI with existing clustering and cell deconvolution tools, demonstrating METI’s robust and consistent performance.


  • Open Access

    Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

    by Sakina A. Plumber, Tiffany Tate, Hikmat Al-Ahmadie, Xiao Chen, Woonyoung Choi, Merve Basar, Chao Lu, Aaron Viny, Ekatherina Batourina, Jiaqi Li, et al.

    Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-basal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable expression in BASQ tumors, we tested the effects of rosiglitazone, Pparg agonist, in a mouse model of BASQ BC. We find that rosiglitazone reduces proliferation while treatment with rosiglitazone plus trametinib, a MEK inhibitor, induces apoptosis and reduces tumor volume by 91% after 1 month. Rosiglitazone and trametinib also induce a shift from BASQ to luminal differentiation in tumors, which our analysis suggests is mediated by retinoid signaling, a pathway known to drive the luminal differentiation program. Our data suggest that rosiglitazone, trametinib, and retinoids, which are all FDA approved, may be clinically active in BASQ tumors in patients.


  • Open Access

    Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis

    by Sangkyou Lee, Jolanta Bondaruk, Yishan Wang, Huiqin Chen, June Goo Lee, Tadeusz Majewski, Rachel D. Mullen, David Cogdell, Jiansong Chen, Ziqiao Wang, et al.